科技圈🎗在花频道📮 | Telegram Webview: TestFlightCN/31945 -

科技圈🎗在花频道📮

过敏性鼻炎治疗研究取得新进展

2025年4月4日，首都医科大学附属北京同仁医院张罗教授团队在国际顶级期刊《自然·医学》（Nature Medicine）发表突破性研究成果——《司普奇拜单抗治疗中重度季节性过敏性鼻炎：一项随机3期试验》（Stapokibart for moderate-to-severe seasonal allergic rhinitis: a randomized phase 3 trial）。
这是全球范围内首次报告基于IL-4Rα靶点的生物制剂治疗季节性过敏性鼻炎的研究成果，亦是中国科学家在过敏性鼻炎领域取得的引领世界的创新性新成果。研究结果显示，司普奇拜单抗能够快速、强效控制患者的鼻部症状，持续显著缓解患者眼部过敏症状，极大提升患者生活质量，且安全性良好。

Nature Medicine

📮投稿 ☘️频道 🌸聊天

www.tg-me.com/id/在花软件新闻投稿频道/com.TestFlightCN/31945

21.2K viewsApr 5 at 12:04

tg-me.com/TestFlightCN/31945

Create: 2025-04-05
Last Update: 2025-05-03 09:07:02

BY 科技圈🎗在花频道📮

Share with your friend now:
tg-me.com/TestFlightCN/31945

在花软件新闻投稿频道 Telegram | DID YOU KNOW?

At a time when the Indian stock market is peaking and has rallied immensely compared to global markets, there are companies that have not performed in the last 10 years. These are definitely a minor portion of the market considering there are hundreds of stocks that have turned multibagger since 2020. What went wrong with these stocks? Reasons vary from corporate governance, sectoral weakness, company specific and so on. But the more important question is, are these stocks worth buying?

Launched in 2013, Telegram allows users to broadcast messages to a following via “channels”, or create public and private groups that are simple for others to access. Users can also send and receive large data files, including text and zip files, directly via the app.The platform said it has more than 500m active users, and topped 1bn downloads in August, according to data from SensorTower.在花软件新闻投稿频道 from id